Colombia's Instituto Nacional de Cancerologia Chooses IntraOp's Mobetron to Help...

Wed Mar 26, 2008 8:00am EDT

* Reuters is not responsible for the content in this press release.

Colombia's Instituto Nacional de Cancerologia Chooses IntraOp's Mobetron to Help Fight Cancer

            Landmark order, first Mobetron in Latin America
SUNNYVALE, Calif.--(Business Wire)--
IntraOp Medical Corporation (OTCBB: IOPM), a provider of
innovative technology solutions for the treatment and eradication of
cancer, announced today that it has received an order for the Mobetron
from the Instituto Nacional de Cancerologia, in Bogota, Colombia. This
will mark the first Mobetron in Latin America, as well as the first
OR-ready radiation device in South America. IntraOp's Mobetron is a
mobile electron beam radiation device that applies a direct
application of intraoperative electron-beam radiation therapy (IOERT)
to a tumor during cancer surgery.

   Instituto Nacional de Cancerologia is a leading public institution
with more than 70 years of experience with many diverse oncological
diseases. Innovators in the treatment of cancer, the Instituto
Nacional de Cancerologia has helped implement techniques for minimally
invasive surgery for cancer and other diseases. Their Pediatric
Oncology Group is a leader in Colombia and one of the most highly
recognized in Latin America.

   The Mobetron enables radiation and surgical oncologists to target
the exact area that requires radiation and to deliver high doses of
radiation directly to the affected tissue during the cancer surgery.
Since the Mobetron is a mobile, self-shielding device, the hospital
can move the Mobetron between operating rooms with ease, avoiding the
high cost of outfitting radiation rooms to accommodate traditional
devices. Key benefits include: better local tumor control, increased
survival rates, shorter treatment cycles and fewer side effects.

   Chief Scientist of IntraOp, Don Goer, said, "We are very pleased
that the Instituto Nacional de Cancerologia has chosen the Mobetron to
be part of their comprehensive cancer treatment program. It is an
honor for IntraOp to be part of such an innovative facility and we
look forward to working with them to extend IOERT to other countries
in the region."

   About IntraOp

   IntraOp Medical Corporation provides innovative technology
solutions for the treatment and eradication of cancer. Founded in
1993, IntraOp is committed to providing the tools doctors need to
administer intraoperative radiation therapy safely and effectively -
for all cancer patients. The company's flagship product, the Mobetron,
is the first fully portable, self-shielding intraoperative electron
radiation therapy device designed for use in any operating room. Key
Mobetron benefits include: increased survival rates, better local
tumor control, shorter treatment cycles, and fewer side effects.
Leading hospitals, from university research centers to specialized
cancer clinics in North America, Europe and Asia, use the Mobetron as
a vital part of their comprehensive cancer program.

   For more information about IntraOp Medical and the Mobetron,
please visit: www.intraopmedical.com

   For more information about Instituto Nacional de Cancerologia,
please visit: www.incancerologia.gov.co

   Forward-looking Statements

   This press release may contain "forward-looking statements" within
the meaning of Section 27A of the 1933 Securities Act and Section 21E
of the 1934 Securities Exchange Act. Actual results could differ
materially, as the result of such factors as competition in the
markets for the company's products and services and the ability of the
Company to execute its plans. By making these forward-looking
statements, the Company can give no assurances that transactions
described in this press release will be successfully completed, and
undertakes no obligation to update these statements for revisions or
changes after the date of this press release.

Affect Strategies
Regina Nisita, 212-398-9680 x145
regina@affectstrategies.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.